To counter a law­suit, Bris­tol-My­ers out­lines how the big Cel­gene buy­out will show­er $187M-plus on Mor­gan Stan­ley

Any­one look­ing to see why in­vest­ment bankers love big time M&A so much should check out Bris­tol-My­ers Squibb’s new SEC fil­ing Thurs­day evening.

In the lead­up to its megamerg­er with Cel­gene, the phar­ma gi­ant has been pep­pered by a slate of law­suits from un­hap­py in­vestors. And to counter one that threat­ened to pos­si­bly de­lay their deal— now fac­ing a cru­cial share­hold­er vote next week that Bris­tol-My­ers is wide­ly ex­pect­ed to win — the Bris­tol-My­ers team spelled out the $187 mil­lion-plus in fees they’re pay­ing to Mor­gan Stan­ley, which of­fered their opin­ion on the fair­ness of the buy­out pact — from the Bris­tol-My­ers per­spec­tive on­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER